01/04/2026
๐๐ง๐ฏ๐ข๐ญ๐๐ญ๐ข๐จ๐ง ๐ญ๐จ ๐๐ญ๐๐ค๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌโ ๐๐๐๐ข๐ง๐๐ซ ๐๐จ๐ง๐๐๐ซ๐๐ง๐๐ ๐๐จ๐ซ ๐๐๐๐๐ฅ๐๐ซ๐๐ญ๐ข๐ง๐ ๐๐๐ซ๐ค๐๐ญ๐ข๐ง๐ ๐๐ฎ๐ญ๐ก๐จ๐ซ๐ข๐ณ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐๐๐๐ฅ๐ญ๐ก ๐ฉ๐ซ๐จ๐๐ฎ๐๐ญ๐ฌ
The Ethiopian Food and Drug Authority [EFDA] is committed to enhancing public health by improving access to safe, high-quality, and efficacious medicines. Over the past few years, EFDA has made significant strides in transforming the regulatory landscape to make it more efficient, transparent, and investor-friendly. One of our proudest achievements is attaining Maturity Level 3 (ML3) status from the World Health Organizationโs Global Benchmarking Tool. This recognition affirms that EFDA operates as a stable, well-functioning, and integrated regulatory system, aligned with international best practices. We have implemented substantial improvements in timeline management for medicine registration through process optimizations and dedicated resources, ensuring faster reviews without compromising quality.
To support manufacturers in navigating the regulatory landscape, and to streamline the approval process for Health products, we are hosting an exclusive webinar.
The objective of this session is to provide direct insights into the Countryโs regulatory requirements, address common pitfalls (bottlenecks) in dossier submission, and accelerate the Marketing Authorization process.
๐๐ฆ๐ฃ๐ช๐ฏ๐ข๐ณ ๐๐ฆ๐ต๐ข๐ช๐ญ๐ด:
๐๐ฐ๐ฑ๐ช๐ค: ๐๐ต๐ณ๐ข๐ต๐ฆ๐จ๐ช๐ฆ๐ด ๐ง๐ฐ๐ณ ๐๐ถ๐ค๐ค๐ฆ๐ด๐ด๐ง๐ถ๐ญ ๐๐ข๐ณ๐ฌ๐ฆ๐ต๐ช๐ฏ๐จ ๐๐ถ๐ต๐ฉ๐ฐ๐ณ๐ช๐ป๐ข๐ต๐ช๐ฐ๐ฏ ๐๐ถ๐ฃ๐ฎ๐ช๐ด๐ด๐ช๐ฐ๐ฏ๐ด
๐๐ข๐ต๐ฆ: [๐๐ฑ๐ณ๐ช๐ญ 16, 2026]
๐๐ช๐ฎ๐ฆ ๐ช๐ฏ ๐ฉ๐ฐ๐ด๐ต ๐ค๐ฐ๐ถ๐ฏ๐ต๐ณ๐บ (๐๐ต๐ฉ๐ช๐ฐ๐ฑ๐ช๐ข): ๐ง๐ณ๐ฐ๐ฎ 11:00 ๐.๐. ๐ต๐ฐ 3:30 ๐ฑ๐ฎ & ๐๐ฏ๐ฅ๐ช๐ข ๐ต๐ช๐ฎ๐ฆ ๐ง๐ณ๐ฐ๐ฎ 1:30๐ฑ๐ฎ ๐ต๐ฐ 5:30 ๐ฑ๐ฎ
๐๐ญ๐ข๐ต๐ง๐ฐ๐ณ๐ฎ: ๐ก๐ฐ๐ฐ๐ฎ
RegistrationLink: https://r4d-org.zoom.us/webinar/register/WN_P6QDmvsqT4GsPit_cV5xTg
๐๐ ๐๐ง๐๐ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:
Regulatory Updates: Overview of Regulatory Requirements for Health Product Dossier submission.
EFDA Strategey for Streamlining Dossier Approval: Strategy for expidite Marketing Authorization of essential medicine.
Market Access Opportunities: Insights into essential medicine needs.
Live Q&A Session: Direct interaction with regulatory reviewers.
We strongly encourage all Marketing Authorization Holders, Indian Drug Manufacturers` Association (IDMA), Manufacturers and your Regulatory Affairs team to participate to ensure your submissions is "regulator-ready," minimizing clock-stops and approval delays.
๐๐ฐ๐ณ ๐ข๐ฏ๐บ ๐ช๐ฏ๐ง๐ฐ๐ณ๐ฎ๐ข๐ต๐ช๐ฐ๐ฏ, ๐ฑ๐ญ๐ฆ๐ข๐ด๐ฆ ๐ค๐ฐ๐ฏ๐ต๐ข๐ค๐ต: ๐๐ฆ๐ฏ๐จ๐ช๐ด๐ต๐ถ ๐๐ฆ๐จ๐ฆ๐ด๐ด๐ฆ: ๐ฎ๐ญ๐ฆ๐จ๐ฆ๐ด๐ด๐ฆ@๐ฆ๐ง๐ฅ๐ข.๐จ๐ฐ๐ท.๐ฆ๐ต +251912105691, ๐๐ข๐ด๐ช๐ญ ๐๐ข๐ช๐ญ๐ฆ๐ฎ๐ข๐ณ๐ช๐ข๐ฎ: ๐ง๐ฉ๐ข๐ช๐ญ๐ฆ๐ฎ๐ข๐ณ๐ช๐ข๐ฎ@๐ฆ๐ง๐ฅ๐ข.๐จ๐ฐ๐ท.๐ฆ๐ต, +251911950615, ๐๐ข๐ฏ๐ช๐ฆ๐ญ ๐๐ข๐ฌ๐ฆ๐ญ: ๐ฅ๐ต๐ข๐ฌ๐ฆ๐ญ๐ฆ@๐ฆ๐ง๐ฅ๐ข.๐จ๐ฐ๐ท.๐ฆ๐ต, +251923145480, ๐ข๐ฏ๐ฅ ๐๐ฉ๐ฆ๐ฐ๐ฅ๐ณ๐ฐ๐ด ๐๐ฆ๐ฏ๐ต๐ข: ๐ต๐ง๐ฆ๐ฏ๐ต๐ข@๐ฆ๐ง๐ฅ๐ข.๐จ๐ฐ๐ท.๐ฆ๐ต, +251911150099